熱門資訊> 正文
Organon将以12亿美元收购Dermavant
2024-09-18 19:44
- Organon (NYSE:OGN) said it will acquire Dermavant, which is a Roivant (ROIV) for $1.2 billion.
- The consideration has an upfront payment of $175 million and a $75 million milestone payment upon regulatory approval, as well as payments of up to $950 million for the achievements of certain commercial milestones.
- Additionally, the firm will pay Dermavant shareholders tiered royalties on net sales.
More on Organon
- Organon & Co.: Cheap With Caveats
- Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
- Eli Lilly, Organon expand distribution deal for migraine drug
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。